16th EBF Open Symposium

November 15 – 17, 2023
Hyatt Regency Barcelona Tower
Barcelona, Spain


We look forward to meeting you at EBF in Barcelona. 

Request a meeting with our team to learn how we help our clients advance their drug modality.

Schedule a Meeting

Speak with our scientific experts onsite to discuss your project.

I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.



BioAgilytix Presentations at the 16th EBF Open Symposium

Track: Gearing up for Bioanalysis for the Next Generation

The increasing complexity of clinical trials for BA

Author: Robert Nelson, PhD, on behalf of EBF – Scientific Officer
Wednesday, November 15, 2023
9:30 – 10:30 a.m.

Track: Hybrid Assays - Strategy

Strategies and Case Studies on the Bioanalysis of Protein Therapeutics and Biomarkers by Immunoaffinity LC-MS/MS

Presenter: Shashank Gorityala, PhD - Associate Director
Wednesday, November 15, 2023
12:30 –12:50 p.m.

Track: ADA Technology

Application of Different Approaches to ADA Domain Specificity Characterization

Author: Christopher Tiedje, PhD - Principal Investigator
Thursday, November 16, 2023
9:40 – 10:00 a.m.

Track: qPCR

qPCR Support of Cell and Gene Therapies - What to Measure and How

Presenter: Amanda Hays, PhD on behalf of AAPS - Scientific Officer
Thursday, November 16, 2023
11:20  – 11:40 a.m.

Development and validation of a multiplex qPCR assay for RCL monitoring

Presenter: Lara Duchstein, M.Sc., - Principal Investigator
Thursday, November 16, 2023
11:40 – 12:00 p.m.

About the event

EBF was founded in 2006 at the initiative of 12 pharmaceutical companies. The goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies and last but not least regulatory issues. Until 2010, EBF membership was limited to pharmaceutical research and development companies with bioanalytical activities in Europe. From 2011 onwards, the EBF welcomed CROs involved in bioanalytical activities in Europe. Since 2010, the EBF became a non-profit organization (vzw) established pursuant to the Belgian Act of 27 June 1921 on non-profit associations, international non-profit associations and foundations. Currently, the EBF counts 75 members (June 2022).

Schedule a meeting with our experts onsite

Speak with our team about how the combination of world-class scientific expertise, outstanding project management, and superior regulatory insight can expedite your advanced therapeutic. You can also fill out the form, and an expert will reach out to schedule a meeting with you onsite.